MegaPro Biomedical Co., Ltd.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
1. Current Progress of Product Development
2. MPB-1514
3. MPB-1523 (IOP Injection)
4. MPB-1734: A New Formulation Anti-cancer Drug
2. MPB-1514
3. MPB-1523 (IOP Injection)
4. MPB-1734: A New Formulation Anti-cancer Drug
Founded Year
2014
Unified Business No.
24765568
Status
Active
Number of Employees
0
Total Paid-in
Capital
793,303,030 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Emerging Stock Exchange(2021)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
MegaPro Biomedical is a clinical-stage nanomedicine company leveraging its proprietary Nano-Particle Platform (PEGylated iron oxide nanoparticles) across diagnostics, cell therapy, and anemia treatment. Key programs include MPB-1523 (liver cancer, Phase III) and MPB-2354 ("Visible Cell Therapy" for Critical Limb Ischemia), targeting global expansion through strategic licensing.
